<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02854748</url>
  </required_header>
  <id_info>
    <org_study_id>19DDI16005</org_study_id>
    <nct_id>NCT02854748</nct_id>
  </id_info>
  <brief_title>Evaluate the Drug-drugs Interaction Between Lobeglitazone and Empagliflozin</brief_title>
  <official_title>A Randomized, Open-label, Multiple Dosing, Crossover Study to Evaluate the Drug-drugs Interaction Between Lobeglitazone and Empagliflozin in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <brief_summary>
    <textblock>
      This study is a randomized, open-label, multiple dosing, crossover study to evaluate the
      drug-drugs interaction between Lobeglitazone and Empagliflozin in healthy male volunteers
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To healthy male subjects of 30, following treatments are administered dosing in each 3
      period(Lobeglitazone or Empagliflozin or Lobe.+Empa.) and wash-out period is a minimum of 7
      days.

      Test Drug 1: Lobeglitazone 0.5mg 1T

      Test Drug 2: Empagliflozin 25mg 1T

      Pharmacokinetic blood samples are collected up to 24hrs.

      Safety, pharmacokinetic and the drug-drugs interaction are assessed.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">September 2016</completion_date>
  <primary_completion_date type="Anticipated">September 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC0-t,ss of Empagliflozin</measure>
    <time_frame>Day 1, 2, 3, 4 (Day 12 - 15, Day 23 - 26): 0 hour, Day 5 (Day 16, Day 27): 0, 0.33, 0.67, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax,ss of Empagliflozin</measure>
    <time_frame>Day 1, 2, 3, 4 (Day 12 - 15, Day 23 - 26): 0 hour, Day 5 (Day 16, Day 27): 0, 0.33, 0.67, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t,ss of Lobeglitazone</measure>
    <time_frame>Day 1, 2, 3, 4 (Day 12 - 15, Day 23 - 26): 0 hour, Day 5 (Day 16, Day 27): 0, 0.33, 0.67, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax,ss of Lobeglitazone</measure>
    <time_frame>Day 1, 2, 3, 4 (Day 12 - 15, Day 23 - 26): 0 hour, Day 5 (Day 16, Day 27): 0, 0.33, 0.67, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tmax,ss of Empagliflozin</measure>
    <time_frame>Day 1, 2, 3, 4 (Day 12 - 15, Day 23 - 26): 0 hour, Day 5 (Day 16, Day 27): 0, 0.33, 0.67, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2,ss of Empagliflozin</measure>
    <time_frame>Day 1, 2, 3, 4 (Day 12 - 15, Day 23 - 26): 0 hour, Day 5 (Day 16, Day 27): 0, 0.33, 0.67, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCinf of Empagliflozin</measure>
    <time_frame>Day 1, 2, 3, 4 (Day 12 - 15, Day 23 - 26): 0 hour, Day 5 (Day 16, Day 27): 0, 0.33, 0.67, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax,ss of Lobeglitazone</measure>
    <time_frame>Day 1, 2, 3, 4 (Day 12 - 15, Day 23 - 26): 0 hour, Day 5 (Day 16, Day 27): 0, 0.33, 0.67, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2,ss of Lobeglitazone</measure>
    <time_frame>Day 1, 2, 3, 4 (Day 12 - 15, Day 23 - 26): 0 hour, Day 5 (Day 16, Day 27): 0, 0.33, 0.67, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCinf of Lobeglitazone</measure>
    <time_frame>Day 1, 2, 3, 4 (Day 12 - 15, Day 23 - 26): 0 hour, Day 5 (Day 16, Day 27): 0, 0.33, 0.67, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Diabetes Mellitus, Type II</condition>
  <arm_group>
    <arm_group_label>Empagliflozin / Lobeglitazone / Empa.+Lobe.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Empagliflozin 25 mg QD for 5 days Period 2: Lobeglitazone 0.5 mg QD for 5 days Period 3: Empagliflozin 25 mg + Lobeglitazone 0.5 mg QD for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Empagliflozin / Empa.+Lobe. / Lobeglitazone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Empagliflozin 25 mg QD for 5 days Period 2: Empagliflozin 25 mg + Lobeglitazone 0.5 mg QD for 5 days Period 3: Lobeglitazone 0.5 mg QD for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lobeglitazone / Empagliflozin / Empa.+Lobe.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Lobeglitazone 0.5 mg QD for 5 days Period 2: Empagliflozin 25 mg QD for 5 days Period 3: Empagliflozin 25 mg + Lobeglitazone 0.5 mg QD for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lobeglitazone / Empa.+Lobe. / Empagliflozin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Lobeglitazone 0.5 mg QD for 5 days Period 2: Empagliflozin 25 mg + Lobeglitazone 0.5 mg QD for 5 days Period 3: Empagliflozin 25 mg QD for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Empa.+Lobe. / Empagliflozin / Lobeglitazone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Empagliflozin 25 mg + Lobeglitazone 0.5 mg QD for 5 days Period 2: Empagliflozin 25 mg QD for 5 days Period 3: Lobeglitazone 0.5 mg QD for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Empa.+Lobe. / Lobeglitazone / Empagliflozin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Empagliflozin 25 mg + Lobeglitazone 0.5 mg QD for 5 days Period 2: Lobeglitazone 0.5 mg QD for 5 days Period 3: Empagliflozin 25 mg QD for 5 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin 25mg</intervention_name>
    <description>Empagliflozin 25 mg QD for 5 days</description>
    <arm_group_label>Empagliflozin / Lobeglitazone / Empa.+Lobe.</arm_group_label>
    <arm_group_label>Empagliflozin / Empa.+Lobe. / Lobeglitazone</arm_group_label>
    <arm_group_label>Lobeglitazone / Empagliflozin / Empa.+Lobe.</arm_group_label>
    <arm_group_label>Lobeglitazone / Empa.+Lobe. / Empagliflozin</arm_group_label>
    <arm_group_label>Empa.+Lobe. / Empagliflozin / Lobeglitazone</arm_group_label>
    <arm_group_label>Empa.+Lobe. / Lobeglitazone / Empagliflozin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lobeglitazone 0.5mg</intervention_name>
    <description>Lobeglitazone 0.5mg QD for 5 days</description>
    <arm_group_label>Empagliflozin / Lobeglitazone / Empa.+Lobe.</arm_group_label>
    <arm_group_label>Empagliflozin / Empa.+Lobe. / Lobeglitazone</arm_group_label>
    <arm_group_label>Lobeglitazone / Empagliflozin / Empa.+Lobe.</arm_group_label>
    <arm_group_label>Lobeglitazone / Empa.+Lobe. / Empagliflozin</arm_group_label>
    <arm_group_label>Empa.+Lobe. / Empagliflozin / Lobeglitazone</arm_group_label>
    <arm_group_label>Empa.+Lobe. / Lobeglitazone / Empagliflozin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin 25mg/Lobeglitazone 0.5mg</intervention_name>
    <description>Empagliflozin 25 mg + Lobeglitazone 0.5mg QD for 5 days</description>
    <arm_group_label>Empagliflozin / Lobeglitazone / Empa.+Lobe.</arm_group_label>
    <arm_group_label>Empagliflozin / Empa.+Lobe. / Lobeglitazone</arm_group_label>
    <arm_group_label>Lobeglitazone / Empagliflozin / Empa.+Lobe.</arm_group_label>
    <arm_group_label>Lobeglitazone / Empa.+Lobe. / Empagliflozin</arm_group_label>
    <arm_group_label>Empa.+Lobe. / Empagliflozin / Lobeglitazone</arm_group_label>
    <arm_group_label>Empa.+Lobe. / Lobeglitazone / Empagliflozin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. A healthy person whose age is in between 19 to 45 during the screening tests

          2. Whose weight is more than 55 kg, BMI is over 18.5 and under 29.9 during the screening
             test. (BMI (kg/m2) = weight (kg) / {height (m)}2)

          3. A male with no congenital or chronic disease in three years, no history of symptoms in
             internal treatment, or no knowledge in the area

          4. Due to the special characteristics of drugs, the participators must be qualified to do
             the clinical screening tests

          5. The participants must have an ability and willingness to participate throughout the
             entire trials

        Exclusion Criteria:

          1. A person who has a history of clinically significant cardiovascular, respiratory,
             liver, kidney, endocrine system, immune system, urinary system diseases, blood-tumor
             diseases, mental illness.

          2. Who had a history of gastrointestinal related disease which can be affected the drug
             absorption (esophageal achalasia, esophagostenosis, esophageal disease, or Crohn's
             disease) or surgeries (except a simple appendectomy or herniotomy)

          3. Who has a history of hypersensitivity reactions to Empagliflozin or Lobeglitazone or
             similar series or other excipient ingredients (aspirin, fibrate, antibiotics, etc.)

          4. A person whose electrocardiogram value includes QTc &gt; 450 msec, PR interval &gt; 200
             msec, QRS duration &gt; 120 msec after screening, or who show clinically significant
             opinion.

          5. Who falls under the following results

               1. Liver Function Test (AST, ALT) are exceeded over 1.5x the upper limit of the
                  normal range

               2. eGFR &lt; 60mL/min/1.73m2

          6. Who shows the vital sign values of more than 150 mmHg or less than 90 mmHg in systolic
             pressure or more than 95 mmHg or less than 60 mmHg in diastolic blood pressure

          7. Who has history of drug abuses or shows a positive result in the urinary drug screen

          8. Who took any prescribed drugs, medicinal plants within the 2 weeks before the first
             day of dosing or takes any over-the-counter drugs or vitamin supplements within 1 week
             (but, if other conditions are met, they can still participate in the clinical test
             through the researcher's judgment)

          9. Who took other investigational drugs or bioequivalence drugs within 3 months before
             the first day of dosing

         10. Who participated in whole blood donation within 2 months before the first of dosing,
             or platelet donations within 1 months. Who received blood a month before the first day
             of dosing

         11. Who constantly drinks alcohol (over 21 units/week, 1 unit = 10 g of pure alcohol) or
             cannot stop drinking alcohol during the clinical test.

         12. Who smokes more than 10 cigarettes per day within 3 months , or who cannot quit
             smoking when hospitalized

         13. Who cannot limit intake of grapefruit or grapefruit containing foods in 48hrs from the
             first dosing of clinical testing drug to collect pharmacokinetic blood samples

         14. Who absorb caffeinated drinks (coffee, tea (black or green tea), soda, coffee flavored
             milk, energy drinks, etc.) or cannot stop absorbing them 24 hours before
             hospitalization until discharging

         15. Not using a reliable contraception, planning a pregnancy during the study

         16. Who has Galactose intolerance, LAPP lactose intolerance, glucose-galactose
             malabsorption or genetic disorders

         17. Person who is not determined unsuitable to participate in this test by the researchers
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Dong A University Hospital</name>
      <address>
        <city>Seo-gu</city>
        <state>Busan</state>
        <zip>49201</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 1, 2016</study_first_submitted>
  <study_first_submitted_qc>August 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 3, 2016</study_first_posted>
  <last_update_submitted>August 7, 2016</last_update_submitted>
  <last_update_submitted_qc>August 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

